{"id":15020,"date":"2026-01-31T05:55:11","date_gmt":"2026-01-31T05:55:11","guid":{"rendered":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/?p=15020"},"modified":"2026-01-31T05:59:18","modified_gmt":"2026-01-31T05:59:18","slug":"trademark-dispute-rexcin-vs-rekin-pharma","status":"publish","type":"post","link":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/","title":{"rendered":"Incidental Use Of A Corporate Name On Product Packaging Does Not Constitute Use As A Trademark"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\" id=\"introduction-trademark-dispute\"><span class=\"ez-toc-section\" id=\"Introduction_Trademark_Dispute\"><\/span>Introduction: Trademark Dispute<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The dispute arose from overlapping names beginning with &#8220;Rexcin&#8221; and &#8220;Rekin,&#8221; but extended to allegations of trademark infringement and passing off for pharmaceutical products. The court&#8217;s analysis underscores the importance of evidentiary proof in establishing actual commercial use, rejecting vague claims of similarity without demonstrable confusion or overlap in trade channels.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #0c0c0c;color:#0c0c0c\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #0c0c0c;color:#0c0c0c\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Introduction_Trademark_Dispute\" >Introduction: Trademark Dispute<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Factual_Background\" >Factual Background<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Rexcin_Pharmaceuticals_Pvt_Ltd\" >Rexcin Pharmaceuticals Pvt. Ltd.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Rexcins_Commercial_Claims\" >Rexcin\u2019s Commercial Claims<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Rexcins_Trademark_Filings\" >Rexcin\u2019s Trademark Filings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Rexcins_Business_Model\" >Rexcin\u2019s Business Model<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Rexcins_Evidence_of_Use\" >Rexcin\u2019s Evidence of Use<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Rekin_Pharma_Pvt_Ltd\" >Rekin Pharma Pvt. Ltd.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Rekins_Product_Launch\" >Rekin\u2019s Product Launch<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Rekins_Online_and_Market_Presence\" >Rekin\u2019s Online and Market Presence<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Rekins_Trademark_Registrations\" >Rekin\u2019s Trademark Registrations<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Legal_Conflict_Between_the_Parties\" >Legal Conflict Between the Parties<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Rekins_Defence\" >Rekin\u2019s Defence<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Inspection_of_Products\" >Inspection of Products<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Procedural_Background\" >Procedural Background<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Listing_And_Notices\" >Listing And Notices<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Settlement_Discussions\" >Settlement Discussions<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/trademark-dispute-rexcin-vs-rekin-pharma\/#Pleadings_And_Arguments\" >Pleadings And Arguments<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n\n\n\n<p>This decision reinforces the principle that trademark rights are grounded in bona fide adoption and continuous use, not merely in registration or nominal presence, and serves as a cautionary tale for entities relying on trade names without active trademark deployment in the marketplace.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"factual-background\"><span class=\"ez-toc-section\" id=\"Factual_Background\"><\/span>Factual Background<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"rexclin-profile\"><span class=\"ez-toc-section\" id=\"Rexcin_Pharmaceuticals_Pvt_Ltd\"><\/span>Rexcin Pharmaceuticals Pvt. Ltd.<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Rexcin Pharmaceuticals Pvt. Ltd., incorporated in 2003, claimed to have coined and used the mark &#8220;Rexcin&#8221; since December 16, 2003, primarily as its trading style and house mark in the pharmaceutical sector. It asserted extensive use across India, displayed on product packaging, with significant promotional expenditure leading to substantial goodwill among the trade, medical professionals, and consumers.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"rexclin-sales-figures\"><span class=\"ez-toc-section\" id=\"Rexcins_Commercial_Claims\"><\/span>Rexcin\u2019s Commercial Claims<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Rexcin&#8217;s sales figures for the financial year 2021\u20132022 were reported at Rs. 830.09 lakhs, purportedly demonstrating sustained commercial activity.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"rexclin-trademark-filings\"><span class=\"ez-toc-section\" id=\"Rexcins_Trademark_Filings\"><\/span>Rexcin\u2019s Trademark Filings<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Trademark applications filed in 2022 for &#8220;Rexcin&#8221; in:\n<ul class=\"wp-block-list\">\n<li>Class 16<\/li>\n\n\n\n<li>Class 44<\/li>\n\n\n\n<li>Class 45<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>All claiming user since 2003 and registered in December 2022.<\/li>\n\n\n\n<li>Applications in:\n<ul class=\"wp-block-list\">\n<li>Class 5 (pharmaceuticals)<\/li>\n\n\n\n<li>Class 35 (trading services)<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>Class 35 accepted and advertised.<\/li>\n\n\n\n<li>Class 5 faced objections due to third-party marks.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"rexclin-business-model\"><span class=\"ez-toc-section\" id=\"Rexcins_Business_Model\"><\/span>Rexcin\u2019s Business Model<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Notably, Rexcin admitted it was not using &#8220;Rexcin&#8221; as a product mark but as part of its corporate identity, functioning as a white-label manufacturer supplying gels and creams to major companies like Sun Pharmaceutical Industries Ltd. and previously Ranbaxy Laboratories Ltd.<\/p>\n\n\n\n<p>Products were sold under distinct third-party trademarks such as:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Gentalene Plus<\/li>\n\n\n\n<li>Silverex Ionic<\/li>\n\n\n\n<li>Moisturex<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"rexclin-evidence\"><span class=\"ez-toc-section\" id=\"Rexcins_Evidence_of_Use\"><\/span>Rexcin\u2019s Evidence of Use<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Invoices from 2004, 2005, 2006, and 2022 showed sales to these entities, but &#8220;Rexcin&#8221; appeared only inconspicuously as the marketer or licensor, not as a source identifier for the goods themselves.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"rekin-profile\"><span class=\"ez-toc-section\" id=\"Rekin_Pharma_Pvt_Ltd\"><\/span>Rekin Pharma Pvt. Ltd.<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>On the other side, Rekin Pharma Pvt. Ltd., incorporated on March 6, 2017, positioned itself as a new-age pharmaceutical company offering affordable medicines across:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Gynaecology<\/li>\n\n\n\n<li>Dermatology<\/li>\n\n\n\n<li>Cardiology<\/li>\n\n\n\n<li>General Medicine<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"rekin-product-launch\"><span class=\"ez-toc-section\" id=\"Rekins_Product_Launch\"><\/span>Rekin\u2019s Product Launch<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>It launched over 60 products in 2017 under the &#8220;Rekin&#8221; brand with formatives such as:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Rekin-SP<\/li>\n\n\n\n<li>Rekin-NP<\/li>\n\n\n\n<li>Rekin-CT<\/li>\n\n\n\n<li>Rekin-P<\/li>\n<\/ul>\n\n\n\n<p>All were Schedule H drugs sold directly to end consumers through B2C channels.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"rekin-online-presence\"><span class=\"ez-toc-section\" id=\"Rekins_Online_and_Market_Presence\"><\/span>Rekin\u2019s Online and Market Presence<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Rekin claimed bona fide adoption of &#8220;Rekin&#8221; as a coined word, with extensive online presence via its website, social media, and third-party platforms, generating visibility and revenue.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"rekin-registrations\"><span class=\"ez-toc-section\" id=\"Rekins_Trademark_Registrations\"><\/span>Rekin\u2019s Trademark Registrations<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Mark<\/th><th>Class<\/th><th>Registration Date<\/th><th>User Claim<\/th><\/tr><\/thead><tbody><tr><td>Rekin Pharma Pvt. Ltd. (Device)<\/td><td>35<\/td><td>February 23, 2021<\/td><td>Since January 1, 2017<\/td><\/tr><tr><td>Rekin-SP (Word)<\/td><td>5<\/td><td>September 1, 2020<\/td><td>Proposed to be used<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"legal-conflict\"><span class=\"ez-toc-section\" id=\"Legal_Conflict_Between_the_Parties\"><\/span>Legal Conflict Between the Parties<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Rexcin learned of Rekin&#8217;s existence in May 2022 upon advertisement of the Class 35 mark, opposed it, leading to suspension, and filed the rectification petition against &#8220;Rekin-SP.&#8221;<\/p>\n\n\n\n<p>Rexcin alleged:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Deceptive similarity by replacing &#8220;XC&#8221; with &#8220;K&#8221;<\/li>\n\n\n\n<li>Addition of generic suffix &#8220;SP&#8221;<\/li>\n\n\n\n<li>Violations under the Trade Marks Act, 1999 including:\n<ul class=\"wp-block-list\">\n<li>Fraud<\/li>\n\n\n\n<li>Lack of distinctiveness<\/li>\n\n\n\n<li>Confusion<\/li>\n\n\n\n<li>Unfair advantage<\/li>\n\n\n\n<li>Passing off<\/li>\n\n\n\n<li>Bad faith<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"rekin-defense\"><span class=\"ez-toc-section\" id=\"Rekins_Defence\"><\/span>Rekin\u2019s Defence<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Rekin countered that:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Its marks were distinctive.<\/li>\n\n\n\n<li>There was no overlap in goods or consumers.<\/li>\n\n\n\n<li>No evidence of confusion despite six years of coexistence.<\/li>\n\n\n\n<li>Rexcin had no Class 5 registration.<\/li>\n\n\n\n<li>Rexcin had no actual trademark use.<\/li>\n<\/ul>\n\n\n\n<p>Rekin further argued that Rexcin operated only in B2B as a supplier without consumer-facing products under &#8220;Rexcin.&#8221;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"inspection-findings\"><span class=\"ez-toc-section\" id=\"Inspection_of_Products\"><\/span>Inspection of Products<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The parties&#8217; products, when inspected, confirmed Rekin&#8217;s prominent use of &#8220;Rekin&#8221; formatives as trademarks, while Rexcin&#8217;s appeared only as trade names on third-party branded items.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"procedural-background\"><span class=\"ez-toc-section\" id=\"Procedural_Background\"><\/span>Procedural Background<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The dispute commenced with Rexcin filing <strong>CS(COMM) 142\/2023<\/strong> in March 2023, seeking permanent injunction against Rekin for trademark infringement, passing off, and related reliefs concerning the marks <strong>&#8220;Rexcin&#8221;<\/strong> and <strong>&#8220;Rekin&#8221;<\/strong>, along with <strong>I.A. 4878\/2023<\/strong> under Order XXXIX Rules 1 and 2 CPC for interim restraint.<\/p>\n\n\n\n<p>Concurrently, Rexcin filed the rectification petition <strong>C.O.(COMM.IPD-TM) 111\/2023<\/strong> under Section 57 of the Trade Marks Act, 1999, challenging Rekin&#8217;s <strong>&#8220;Rekin-Sp&#8221;<\/strong> registration (No. 3541661) on grounds of absolute and relative prohibitions, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Lack of distinctiveness<\/li>\n\n\n\n<li>Deceptive similarity<\/li>\n\n\n\n<li>Confusion<\/li>\n\n\n\n<li>Unfair advantage<\/li>\n\n\n\n<li>Passing off<\/li>\n\n\n\n<li>Bad faith<\/li>\n\n\n\n<li>Arbitrary grant<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"listing-and-notices\"><span class=\"ez-toc-section\" id=\"Listing_And_Notices\"><\/span>Listing And Notices<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The petition was listed before the court on March 14, 2023, with notice issued to Rekin on September 20, 2023.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"settlement-discussions\"><span class=\"ez-toc-section\" id=\"Settlement_Discussions\"><\/span>Settlement Discussions<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>On March 4, 2024, a coordinate bench queried both parties on settling by restricting <strong>&#8220;Rekin&#8221;<\/strong> to corporate name use only, suggesting mediation if amenable, and listed the matter for May 13, 2024.<\/p>\n\n\n\n<p>No settlement occurred, and the matters were argued together, with the court deciding to first resolve the rectification petition on rights in the marks before addressing the interim application.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"pleadings-and-arguments\"><span class=\"ez-toc-section\" id=\"Pleadings_And_Arguments\"><\/span>Pleadings And Arguments<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Rekin filed its reply, contending:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Bona fide prior adoption<\/li>\n\n\n\n<li>Distinct spheres (B2C vs. B2B)<\/li>\n\n\n\n<li>No confusion evidence<\/li>\n\n\n\n<li>Rexcin&#8217;s lack of Class 5 use or registration<\/li>\n<\/ul>\n\n\n\n<p>Rexcin&#8217;s rejoinder emphasized its tradename goodwill and deceptive similarity.<\/p>\n\n\n\n<p>The court heard arguments and perused records, including:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Evidence Considered<\/th><th>Observation<\/th><\/tr><\/thead><tbody><tr><td>Invoices<\/td><td>Examined for commercial use<\/td><\/tr><tr><td>Chartered Accountant Certificates<\/td><td>Deemed incomplete<\/td><\/tr><tr><td>Physical Product Samples<\/td><td>Placed on record<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Introduction: Trademark Dispute The dispute arose from overlapping names beginning with &#8220;Rexcin&#8221; and &#8220;Rekin,&#8221; but extended to allegations of trademark infringement and passing off for pharmaceutical products. The court&#8217;s analysis underscores the importance of evidentiary proof in establishing actual commercial use, rejecting vague claims of similarity without demonstrable confusion or overlap in trade channels. This<\/p>\n","protected":false},"author":56,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"two_page_speed":[],"_jetpack_memberships_contains_paid_content":false,"_joinchat":[],"footnotes":""},"categories":[21],"tags":[28],"class_list":{"0":"post-15020","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-intellectual-property","7":"tag-top-news"},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts\/15020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/users\/56"}],"replies":[{"embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/comments?post=15020"}],"version-history":[{"count":0,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts\/15020\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/media?parent=15020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/categories?post=15020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/tags?post=15020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}